The 5α-reductase inhibitor Dutasteride but not Finasteride protects dopamine neurons in the MPTP mouse model of Parkinson's disease

Neuropharmacology

Volumn 97, Issue , 2015, Pages 86-94

  Litim, Nadhir ^a,b   Bourque, Mélanie ^a,b   Al Sweidi, Sara ^a,b   Morissette, Marc ^a   Di Paolo, Thérèse ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

Author keywords

Dopamine; Dutasteride; Finasteride; MPTP; Neuroprotection; Striatum

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; ANDROSTANOLONE; DOPAMINE; DOPAMINE TRANSPORTER; DUTASTERIDE; FINASTERIDE; HOMOVANILLIC ACID; MESSENGER RNA; SEROTONIN; STEROID 5ALPHA REDUCTASE INHIBITOR; TESTOSTERONE; TYROSINE 3 MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORTER 2; NEUROPROTECTIVE AGENT; SLC18A2 PROTEIN, MOUSE; VESICULAR MONOAMINE TRANSPORTER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINERGIC NERVE CELL; MALE; MOUSE; MPTP-INDUCED PARKINSONISM; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; SEROTONIN BRAIN LEVEL; SUBSTANTIA NIGRA PARS COMPACTA; TESTOSTERONE BLOOD LEVEL; ANIMAL; BLOOD; C57BL MOUSE; COMPARATIVE STUDY; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; MPTP POISONING; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME FACTOR;

3,4-DIHYDROXYPHENYLACETIC ACID; 5-ALPHA REDUCTASE INHIBITORS; ANIMALS; CORPUS STRIATUM; DIHYDROTESTOSTERONE; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINERGIC NEURONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DUTASTERIDE; FINASTERIDE; HOMOVANILLIC ACID; MALE; MICE, INBRED C57BL; MPTP POISONING; NEUROPROTECTIVE AGENTS; PARS COMPACTA; RNA, MESSENGER; TESTOSTERONE; TIME FACTORS; TYROSINE 3-MONOOXYGENASE; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84934926218     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.05.015     Document Type: Article

References (52)

1. S.O. Adeosun, X. Hou, Y. Jiao, B. Zheng, S. Henry, R. Hill, Z. He, A. Pani, P. Kyle, X. Ou, T. Mosley, J.M. Farley, C. Stockmeier, I. Paul, S. Bigler, R.D. Brinton, R. Smeyne, and J.M. Wang Allopregnanolone reinstates tyrosine hydroxylase immunoreactive neurons and motor performance in an MPTP-lesioned mouse model of Parkinson's disease PLoS ONE 7 2012 e50040 10.1371/journal.pone.0050040
2. R.C. Agís-Balboa, G. Pinna, A. Zhubi, E. Maloku, M. Veldic, E. Costa, and A. Guidotti Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis Proc. Natl. Acad. Sci. U. S. A. 103 2006 14602 14607 10.1073/pnas.0606544103
3. B. Azzolina, K. Ellsworth, S. Andersson, W. Geissler, H.G. Bull, and G.S. Harris Inhibition of rat α-reductases by finasteride: evidence for isozyme differences in the mechanism of inhibition J. Steroid Biochem. Mol. Biol. 61 1997 55 64 10.1016/S0960-0760(97)00002-2
4. J.B. Becker Gender differences in dopaminergic function in striatum and nucleus accumbens Pharmacol. Biochem. Behav. 64 1999 803 812 10.1016/S0091-3057(99)00168-9
5. D. Belelli, and J.J. Lambert Neurosteroids: endogenous regulators of the GABA(A) receptor Nat. Rev. Neurosci. 6 2005 565 575 10.1038/nrn1703
6. M. Bortolato, R. Frau, M. Orrù, Y. Bourov, F. Marrosu, G. Mereu, P. Devoto, and G.L. Gessa Antipsychotic-like properties of 5-alpha-reductase inhibitors Neuropsychopharmacology 33 2008 3146 3156 10.1038/npp.2008.39
7. M. Bourque, D.E. Dluzen, and T. Di Paolo Neuroprotective actions of sex steroids in Parkinson's disease Front. Neuroendocrinol. 30 2009 142 157 10.1016/j.yfrne.2009.04.014
8. M. Bourque, M. Morissette, and T. Di Paolo Raloxifene activates G protein-coupled estrogen receptor 1/Akt signaling to protect dopamine neurons in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice Neurobiol. Aging 35 2014 2347 2356 10.1016/j.neurobiolaging.2014.03.017
9. H.G. Bull, M. Garcia-Calvo, S. Andersson, W.F. Baginsky, H.K. Chan, D.E. Ellsworth, R.R. Miller, R.A. Stearns, R.K. Bakshi, G.H. Rasmusson, R.L. Tolman, R.W. Myers, J.W. Kozarich, and G.S. Harris Mechanism-based inhibition of human steroid 5α-reductase by Finasteride: enzyme-catalyzed formation of NADP-dihydrofinasteride, a potent bisubstrate analog inhibitor J. Am. Chem. Soc. 118 1996 2359 2365 10.1021/ja953069t
10. R.E. Burke, and K. O'Malley Axon degeneration in Parkinson's disease Exp. Neurol. 246 2013 72 83 10.1016/j.expneurol.2012.01.011
11. E.E. Calle, H.S. Feigelson, J.S. Hildebrand, L.R. Teras, M.J. Thun, and C. Rodriguez Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype Cancer 115 2009 936 945 10.1002/cncr.24101
12. S. Callier, M. Morissette, M. Grandbois, D. Pélaprat, and T. Di Paolo Neuroprotective properties of 17beta-estradiol, progesterone, and raloxifene in MPTP C57Bl/6 mice Synapse 41 2001 131 138 10.1002/syn.1067
13. R.V. Clark, D.J. Hermann, G.R. Cunningham, T.H. Wilson, B.B. Morrill, and S. Hobbs Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor J. Clin. Endocrinol. Metab. 89 2004 2179 2184 10.1210/jc.2003-030330
14. L.J. Currie, M.B. Harrison, J.M. Trugman, J.P. Bennett, and G.F. Wooten Postmenopausal estrogen use affects risk for Parkinson disease Arch. Neurol. 61 2004 886 888 10.1001/archneur.61.6.886
15. M. D'Astous, M. Morissette, B. Tanguay, S. Callier, and T. Di Paolo Dehydroepiandrosterone (DHEA) such as 17beta-estradiol prevents MPTP-induced dopamine depletion in mice Synapse 47 2003 10 14 10.1002/syn.10145
16. F. di Michele, S. Luchetti, G. Bernardi, E. Romeo, and P. Longone Neurosteroid and neurotransmitter alterations in Parkinson's disease Front. Neuroendocrinol. 34 2013 132 142
17. D.A. Finn, A.S. Beadles-Bohling, E.H. Beckley, M.M. Ford, K.R. Gililland, R.E. Gorin-Meyer, and K.M. Wiren A new look at the 5alpha-reductase inhibitor Finasteride CNS Drug Rev. 12 2006 53 76 10.1111/j.1527-3458.2006.00053.x
18. V. Francardo, F. Bez, T. Wieloch, H. Nissbrandt, K. Ruscher, and M.A. Cenci Pharmacological stimulation of sigma-1 receptors has neurorestorative effects in experimental parkinsonism Brain 137 2014 1998 2014 10.1093/brain/awu107
19. K. Franklin, and G. Paxinos The Mouse Brain in Stereotaxic Coordinates 2008
20. R. Frau, G. Pillolla, V. Bini, S. Tambaro, P. Devoto, and M. Bortolato Inhibition of 5α-reductase attenuates behavioral effects of D1-, but not D2-like receptor agonists in C57BL/6 mice Psychoneuroendocrinology 38 2013 542 551 10.1016/j.psyneuen.2012.07.014
21. H.-M. Gao, and J.-S. Hong Gene-environment interactions: key to unraveling the mystery of Parkinson's disease Prog. Neurobiol. 94 2011 1 19 10.1016/j.pneurobio.2011.03.005
22. F.W. George, D.W. Russell, and J.D. Wilson Feed-forward control of prostate growth: dihydrotestosterone induces expression of its own biosynthetic enzyme, steroid 5 alpha-reductase Proc. Natl. Acad. Sci. U. S. A. 88 1991 8044 8047 10.1073/pnas.88.18.8044
23. K.A. Harrington, S.J. Augood, A.E. Kingsbury, O.J. Foster, and P.C. Emson Dopamine transporter (Dat) and synaptic vesicle amine transporter (VMAT2) gene expression in the substantia nigra of control and Parkinson's disease Brain Res. Mol. Brain Res. 36 1996 157 162 10.1016/0169-328X(95)00278-Z
24. T. Hayashi, and T.-P. Su Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders CNS Drugs 18 2004 269 284 10.2165/00023210-200418050-00001
25. M. Kilbourn, and K. Frey Striatal concentrations of vesicular monoamine transporters are identical in MPTP-sensitive (C57BL/6) and -insensitive (CD-1) mouse strains Eur. J. Pharmacol. 307 1996 227 232 10.1016/0014-2999(96)00252-X
26. E. Küppers, T. Ivanova, M. Karolczak, and C. Beyer Estrogen: a multifunctional messenger to nigrostriatal dopaminergic neurons J. Neurocytol. 29 2000 375 385 10.1023/A:1007165307652
27. F. Labrie, A. Bélanger, P. Bélanger, R. Bérubé, C. Martel, L. Cusan, J. Gomez, B. Candas, I. Castiel, V. Chaussade, C. Deloche, and J. Leclaire Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women J. Steroid Biochem. Mol. Biol. 99 2006 182 188 10.1016/j.jsbmb.2006.02.004
28. B.C. Lund, K.A. Bever-Stille, and P.J. Perry Testosterone and andropause: the feasibility of testosterone replacement therapy in elderly men Pharmacotherapy 19 1999 951 956
29. A. Mayerhofer, A. Bartke, and R.W. Steger Catecholamine effects on testicular testosterone production in the gonadally active and the gonadally regressed adult golden hamster Biol. Reprod. 40 1989 752 761 10.1095/biolreprod40.4.752
30. R.C. Melcangi, and G.C. Panzica Allopregnanolone: state of the art Prog. Neurobiol. 113 2014 1 5 10.1016/j.pneurobio.2013.09.005
31. D.B.D. Miller, S.F.S. Ali, J.P.J. O'Callaghan, and S.C.S. Laws The impact of gender and estrogen on striatal dopaminergic neurotoxicity Ann. N. Y. Acad. Sci. 844 1998 153 165 10.1111/j.1749-6632.1998.tb08230.x
32. M. Morissette, S. Sweidi Al, S. Callier, and T. Di Paolo Estrogen and SERM neuroprotection in animal models of Parkinson's disease Mol. Cell. Endocrinol. 290 2008 60 69 10.1016/j.mce.2008.04.008
33. N. Narboux-Nême, C. Sagné, S. Doly, S.L. Diaz, C.B.P. Martin, G. Angenard, M.-P. Martres, B. Giros, M. Hamon, L. Lanfumey, P. Gaspar, and R. Mongeau Severe serotonin depletion after conditional deletion of the vesicular monoamine transporter 2 gene in serotonin neurons: neural and behavioral consequences Neuropsychopharmacology 36 2011 2538 2550 10.1038/npp.2011.142
34. P. Negri-Cesi, A. Poletti, and F. Celotti Metabolism of steroids in the brain: a new insight into the role of 5alpha-reductase and aromatase in brain differentiation and functions J. Steroid Biochem. Mol. Biol. 58 1996 455 466 10.1016/0960-0760(96)00083-0
35. M.S. Okun, W.M. McDonald, and M.R. DeLong Refractory nonmotor symptoms in male patients with Parkinson disease due to testosterone deficiency: a common unrecognized comorbidity Arch. Neurol. 59 2002 807 811 10.1001/archneur.59.5.807
36. S. Paba, R. Frau, S.C. Godar, P. Devoto, F. Marrosu, and M. Bortolato Steroid 5α-reductase as a novel therapeutic target for schizophrenia and other neuropsychiatric disorders Curr. Pharm. Des. 17 2011 151 167 10.2174/138161211795049589
37. S. Przedborski, and M. Vila The 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model Ann. N. Y. Acad. Sci. 991 2006 189 198 10.1111/j.1749-6632.2003.tb07476.x
38. P. Ragonese, M. D'Amelio, G. Salemi, P. Aridon, M. Gammino, A. Epifanio, L. Morgante, and G. Savettieri Risk of Parkinson disease in women: effect of reproductive characteristics Neurology 62 2004 2010 2014 10.1212/WNL.62.11.2010
39. R. Rozati, P.P. Reddy, P. Reddanna, and R. Mujtaba Role of environmental estrogens in the deterioration of male factor fertility Fertil. Steril. 78 2002 1187 1194
40. R. Ruffoli, M.A. Giambelluca, M.C. Scavuzzo, L. Pasquali, F. Giannessi, and F. Fornai MPTP-induced Parkinsonism is associated with damage to Leydig cells and testosterone loss Brain Res. 1229 2008 218 223 10.1016/j.brainres.2008.06.116
41. D.W. Russell, and J.D. Wilson Steroid 5 alpha-reductase: two genes/two enzymes Annu. Rev. Biochem. 63 1994 25 61 10.1146/annurev.bi.63.070194.000325
42. R. Saunders-Pullman, J. Gordon-Elliott, M. Parides, S. Fahn, H.R. Saunders, and S. Bressman The effect of estrogen replacement on early Parkinson's disease Neurology 52 1999 1417 1421 10.1212/WNL.52.7.1417
43. K.M. Shaw, A.J. Lees, and G.M. Stern The impact of treatment with levodopa on Parkinson's disease Q. J. Med. 49 1980 283 293
44. K.M. Smith, and N. Dahodwala Sex differences in Parkinson's disease and other movement disorders Exp. Neurol. 259 2014 44 56 10.1016/j.expneurol.2014.03.010
45. V. Soskić, M. Klemm, T. Proikas-Cezanne, G.P. Schwall, S. Poznanović, W. Stegmann, K. Groebe, H. Zengerling, R. Schoepf, M. Burnet, and A. Schrattenholz A connection between the mitochondrial permeability transition pore, autophagy, and cerebral amyloidogenesis J. Proteome Res. 7 2008 2262 2269 10.1021/pr700686x
46. B. Stoffel-Wagner Neurosteroid biosynthesis in the human brain and its clinical implications Ann. N. Y. Acad. Sci. 1007 2003 64 78 10.1196/annals.1286.007
47. T.P. Su, E.D. London, and J.H. Jaffe Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems Science 240 1988 219 221 10.1126/science.2832949
48. A.E. Thigpen, and D.W. Russell Four-amino acid segment in steroid 5 alpha-reductase 1 confers sensitivity to finasteride, a competitive inhibitor J. Biol. Chem. 267 1992 8577 8583
49. J.M. Torres, J.M. Torres, J.M. Torres, E. Ortega, E. Ortega, and E. Ortega Precise quantitation of 5α-reductase type 1 mRNA by RT-PCR in rat liver and its positive regulation by testosterone and dihydrotestosterone Biochem. Biophys. Res. Commun. 308 2003 469 473 10.1016/S0006-291X(03)01423-2
50. K.F. Winklhofer, and C. Haass Mitochondrial dysfunction in Parkinson's disease Biochim. Biophys. Acta (BBA) Mol. Basis Dis. 1802 2010 29 44 10.1016/j.bbadis.2009.08.013
51. Y. Xu, S.L. Dalrymple, R.E. Becker, S.R. Denmeade, and J.T. Isaacs Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers Clin. Cancer Res. 12 2006 4072 4079 10.1158/1078-0432.CCR-06-0184
52. M.B.H. Youdim, L. Kupershmidt, T. Amit, and O. Weinreb Promises of novel multi-target neuroprotective and neurorestorative drugs for Parkinson's disease Parkinsonism Relat. Disord. 20 Suppl. 1 2014 S132 S136 10.1016/S1353-8020(13)70032-4